What You Should Know:
– EVERSANA and Waltz Health have announced a merger valued at $6B to form a unified healthcare platform that will redefine pharmaceutical commercialization and patient access.
– The merger combines Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model with EVERSANA’s global commercialization services. The new organization aims to deliver a next-generation approach to drug access and value in the U.S. healthcare system, particularly for high-cost drug classes like GLP-1s.
End-to-End Model for Life Sciences
EVERSANA has been a leader in the pharma commercialization industry, serving the top 50 pharma and biotech companies globally. Waltz Health’s technology platform, which includes an AI-powered prescription routing and affordability solution, complements this foundation by connecting patients, health insurers, self-insured employers, governments, and pharmacy benefit managers (PBMs).
The union gives life sciences companies a direct connection to payers and provides unmatched reach and execution power across several key areas:
- Pharma Commercialization: The combined organization integrates patient services, field teams, digital marketing, reimbursement support, and real-world evidence, all powered by modern software infrastructure.
- Payer Connectivity: Waltz’s direct-to-payer and direct-to-patient solutions will supercharge the EVERSANA COMPLETE Commercialization™ model, giving manufacturers channels to reach millions of covered lives.
- Drug Affordability & Adherence: The companies will enable net-price models, copay optimization, and integrated pharmacy routing to reduce patient abandonment and increase therapeutic persistence.
- Specialty Pharmacy Infrastructure: Through Waltz Connect, EVERSANA now has a fully integrated, URAC-accredited specialty pharmacy network designed for high-cost and limited distribution drugs.
As part of the acquisition, Mark Thierer, Co-founder and CEO of Waltz Health and Chairman of EVERSANA, will serve as CEO of the combined organization. “This is a pivotal moment for the healthcare industry,” said Thierer. “By combining EVERSANA’s pharma services with Waltz’s technology-enabled payer solutions, we’re creating a unified platform that connects life sciences innovation directly to the organizations and individuals we’re meant to serve. This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step.”
